Ambroxol Trial in Parkinson’s Dementia – What We Learned

A recent study tested ambroxol, a common cough medicine, to see if it could help people with Parkinson’s disease dementia. Who was in the study? 55 people aged 50 or older, all with Parkinson’s dementia. They took either a low dose, a high dose of ambroxol, or a placebo (dummy pill) for one year. Was it safe? Yes. Most people handled ambroxol well. A few had minor stomach issues, but there were no serious side effects. Did it reach the brain? Yes. The higher dose of ambroxol helped increase a brain enzyme called GCase, which is linked to better brain cell cleaning and protection. This is a good sign the drug is doing what it’s supposed to. Did memory or thinking improve? Not in this trial. People taking ambroxol didn’t show big changes in memory or thinking compared to those on the placebo. But the study was small, so more research is needed. What does this mean? Ambroxol looks safe for long-term use in people with Parkinson’s It gets into the brain and hits its target It might help protect brain cells, but we need bigger trials to know if it improves symptoms Next steps: Larger studies will help confirm if ambroxol can slow down or improve Parkinson’s in the long run.